Recent developments highlight KALA BIO's strategic shift to AI platform development, leadership changes, financial restructuring, and significant stock price volatility linked to clinical trial outcomes.

• KALA BIO entered into an exclusive license agreement for the Researgency AI research platform with Younet AI in March 2026 to develop on-premises AI infrastructure for biotech clients [S1].
• The company cleared its debt with Oxford Finance, signaling a financial restructuring and fresh start as of January 2026 [N2].
• KALA BIO's stock surged 75% in March 2026 following announcements related to AI healthcare breakthroughs [N1].
• The Phase 2b CHASE study for KPI-012 failed to meet primary endpoints, resulting in a share price plunge over 90% in late September 2025 [N4].
• Following the trial failure, KALA BIO's stock crashed 88% within a month, reflecting market reaction to clinical setbacks [N3].
• Todd Bazemore was promoted to President and CEO in September 2025, indicating leadership changes during the transition [N6].
• The company completed patient enrollment in the CHASE Phase 2b trial in July 2025, anticipating topline results by Q3 2025 [N7].
• Wall Street analysts showed interest in KALA BIO ahead of major clinical trial data readouts in mid-2025, reflecting market attention to the company's clinical programs [N8].

KALA BIO's accumulated clinical data and intellectual property from its MSC-S biologics program provide a valuable asset base for developing its Researgency AI platform. The exclusive license agreement with Younet AI enables the company to offer a dedicated, secure AI infrastructure tailored to biotech workflows, potentially addressing unmet needs in data privacy and regulatory compliance. Successful validation of the platform using proprietary datasets and strategic customer engagements could establish KALA BIO as a specialized AI partner in the biotechnology sector. The company's strong liquidity position supports ongoing development and strategic initiatives.

KALA BIO faces significant challenges including the failure of its lead biologic candidate KPI-012 in clinical trials, leading to discontinuation of its core therapeutic development. The AI platform business is at an early stage with uncertain commercial viability and significant development risks. Regulatory, cybersecurity, and data privacy challenges are heightened given the sensitive nature of biotech data. The company’s ability to monetize legacy biologics assets and successfully commercialize the AI platform is uncertain. Financial losses and stock price volatility reflect these risks, and the competitive landscape for AI in biotech is intense and rapidly changing.

KALA BIO's moat is currently limited due to its transition from clinical-stage biopharmaceutical development to an early-stage AI platform business. The company holds proprietary intellectual property and extensive clinical datasets from its KPI-012 program, which provide a unique foundation for its AI platform development. Its exclusive license for the Researgency AI platform and focus on on-premises deployment tailored to biotech compliance and data privacy requirements may offer differentiation. However, the AI platform market for biotechnology is competitive and rapidly evolving, and KALA BIO's ability to establish a defensible position depends on successful platform development, customer adoption, and strategic partnerships.

• Clinical Development Risk: The failure of KPI-012 in the Phase 2b CHASE trial led to discontinuation of the biologics program, highlighting the risk of unsuccessful clinical outcomes impacting business viability.
• Early-Stage AI Platform Development: The Researgency AI platform is in early development and validation stages, with uncertain commercial adoption and execution risks.
• Regulatory and Compliance Challenges: The company must navigate complex regulatory frameworks for biotech data and AI applications, with accountability for compliance remaining with customers.
• Cybersecurity and Data Privacy Risks: Processing sensitive biological and clinical data increases exposure to cybersecurity threats and privacy compliance risks.
• Financial and Liquidity Risks: Continued net losses and reliance on liquidity and financing pose risks to sustaining operations and funding strategic initiatives.
• Market and Competitive Risks: The AI platform market for biotechnology is competitive and rapidly evolving, with potential adverse developments affecting KALA BIO's business.

• KALA BIO, Inc. is a biopharmaceutical company transitioning to develop a dedicated, on-premises AI infrastructure platform for the biotechnology industry as of the 2025 fiscal year end [S1].
• Historically, KALA BIO focused on research, development, and commercialization of therapies for rare and severe eye diseases, with lead product candidate KPI-012, a mesenchymal stem cell secretome (MSC-S) therapy for persistent corneal epithelial defects (PCED) [S1].
• KPI-012 was acquired from Combangio, Inc. in November 2021 and underwent clinical development including a Phase 1b trial and a Phase 2b CHASE trial [S1].
• The CHASE Phase 2b trial did not meet its primary endpoints by September 2025, leading to discontinuation of KPI-012 and the MSC-S platform development [S1].
• Post-trial, the company is evaluating strategic alternatives for its biologics assets and focusing on developing an AI platform leveraging intellectual property and datasets from prior clinical programs [S1].
• On March 3, 2026, KALA BIO entered into an exclusive license agreement with Younet AI for the Researgency AI research platform, intended for on-premises deployment in biotech and pharmaceutical client environments [S1].
• The Researgency platform aims to provide multi-agent orchestration for biotech workflows, integration with biomedical databases, audit and compliance features, and private-cloud or on-premises deployment options [S1].
• KALA BIO plans to use its KPI-012 clinical development dataset, including data from 79 patients across 37 clinical sites, as a proof-of-concept validation environment for Researgency [S1].
• The company intends to offer Researgency as a platform-as-a-service with implementation support, maintenance subscriptions, and data analytics services targeting mid-size biotech companies, CROs, and pharmaceutical companies [S1].
• KALA BIO reported a net loss of $26.98 million and basic and diluted EPS of -$3.31 for the fiscal year ended December 31, 2025 [S1].
• As of December 31, 2025, KALA BIO held $7.56 million in cash and cash equivalents, with current assets of $9.49 million and current liabilities of $2.49 million, resulting in a current ratio of 3.81 and a cash ratio of 7.01 [S1].
• The company cleared its debt with Oxford Finance as reported in January 2026 [N2].
• KALA BIO experienced significant stock price volatility related to clinical trial outcomes, including a share price plunge over 90% following the failure of KPI-012 in the Phase 2b CHASE study in September 2025 [N4][N3].
• Leadership changes included promotion of Todd Bazemore to President and CEO in September 2025 [N6].
• The company is pursuing strategic partnerships, licensing, and collaborations for both its biologics portfolio and AI platform business [S1].
• Risks include the early stage of AI platform development, regulatory and compliance challenges, cybersecurity risks due to processing sensitive biological data, and uncertainty regarding monetization of legacy biologics assets [S1].